Experimental donor immune cells target Hard-to-Treat lymphoma
NCT ID NCT06285422
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 39 times
Summary
This early-phase trial tests SC262, a therapy made from donor immune cells (CAR T cells) designed to attack a protein called CD22 on lymphoma cells. It is for people with non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The main goal is to check safety, but researchers will also look for signs that the therapy shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
The University of Kansas Hospital
Kansas City, Kansas, 66160, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SC262 (a type of immune cell therapy called CAR T cells, made from donor cells)
What this could lead to
If it works, this could offer a new treatment option for people with non-Hodgkin's lymphoma that has not responded to other therapies.
What could go wrong
This is a very early (Phase 1) and small study (6 participants). It primarily tests safety, not effectiveness. The therapy may not work or could cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.